

## 2016: Onward and Upward

Where did 2015 go? Time truly flies when science is going well, and editing occupies a greater portion of your time. This latter point is all positive, as *ACS Chemical Neuroscience* continues to gain momentum and reach new heights. In 2014, *ACS Chemical Neuroscience* had 1877 citations and an impact factor of 4.362. Final numbers will not be available until June 2016, but *ACS Chemical Neuroscience* is on track to do much better. As of mid-December 2015, citations exceeded 2200, and we are projecting an impact factor above 4.5. At present, the h-index for *ACS Chemical Neuroscience* is 31, with an average of 7.75 citations per article. Importantly, the statistics are not driven by a handful of highly cited articles. In parallel, both the number and quality of submissions continues to increase. All of us at *ACS Chemical Neuroscience* (Myself, Jitesh Soares, Anne Andrews, Jacob Hooker, and Kathryn Cunningham) thank our authors for entrusting the dissemination of your science with us, and a heartfelt thank you to the amazing reviewers that freely offer their time to evaluate manuscripts to ensure high quality. All of us at *ACS Chemical Neuroscience* extend sincere gratitude to Professor Thomas Knöpfel (Imperial College London) for his service as an Associate Editor, and wish him well as he rotates off of the Editorial Board. We will be adding a new International Associate Editor in 2016, and numerous Special Issues will publish in 2016 as well.

Reviews. *ACS Chemical Neuroscience* is actively soliciting Review Articles focused on neuropharmacology, small molecule therapeutics/imaging agents, and other topics under the *ACS Chemical Neuroscience* umbrella. Presubmission inquiries are welcomed, but not required. In the same vein, we hope to publish 3–4 *Classics in Chemical Neuroscience* pieces in 2016, and I encourage anyone interested to email me ([eic@chemneuro.acs.org](mailto:eic@chemneuro.acs.org)) with the therapeutic they wish to profile. This series has become both highly cited and read, and we hope to further expand the content.

As we enter 2016, IMS Health forecasts positive growth for pharmaceuticals.<sup>1</sup> Global drug spending is projected to increase 30% by 2020 to a market size of \$1.4 trillion, with a global patient use of 4–5 trillion doses (a 24% increase from 2015).<sup>1</sup> Interestingly, IMS Health also reports that 225 new medicines will enter the market by 2020 (~1/3 for oncology), and that 90% of dispensed U.S. medicines will be generics! The next 5 years will be very exciting to watch.

Finally, in 2010, I wrote an editorial about our daughter Paige, and her diagnosis and battle with neuroblastoma.<sup>2</sup> Out of a terrible time, writing about the science of the disease and treatments was therapeutic for me, and as a result many people have been interested in Paige's story. I am very happy to report that Paige is now considered "cured"—5 years with no evidence of disease, and Paige had her last survivorship clinic appointment. Pediatric oncology needs more attention—more research—more patient advocacy. Paige's story is rare—most do not have a favorable outcome. While my family is relieved and truly has something wonderful to celebrate this holiday season, we are also aware that many families—many patients—are not so fortunate.

Craig W. Lindsley, Editor-in-Chief

### AUTHOR INFORMATION

#### Notes

The views expressed in the editorial are those of the author and not necessarily the views of the ACS.

### REFERENCES

- (1) Constantino, T. (2015) IMS Health Forecasts Global Drug Spending to Increase 30% by 2020, to \$1.4 Trillion, As Medicine Use Gap Narrows. IMS Institute for Healthcare Informatics, Danbury, CT, [www.imshealth.com](http://www.imshealth.com).
- (2) Lindsley, C. W. (2010) Horner's Syndrome and Neuroblastoma: Our Family's Odyssey with Disorders of the Sympathetic Nervous System. *ACS Chem. Neurosci.* 1, 649–650.

Published: January 20, 2016

